Management of cancer pain: ESMO Clinical Practice Guidelines

Annals of Oncology

Volumn 21, Issue SUPPL. 5, 2010, Pages

  Jost, L ^a   Roila, F ^b  

^a KANTONSSPITAL   (Switzerland)

^b S MARIA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMITRIPTYLINE; BUPRENORPHINE; CARBAMAZEPINE; CHLORPROMAZINE; CLOMIPRAMINE; CODEINE; DEXTROPROPOXYPHENE; DICLOFENAC; DIHYDROCODEINE; FENTANYL; FLUOXETINE; GABAPENTIN; HALOPERIDOL; HYDROMORPHONE; IBUPROFEN; KETOPROFEN; MEFENAMIC ACID; METHADONE; MORPHINE; NALOXONE; NAPROXEN; NICOMORPHINE; NONSTEROID ANTIINFLAMMATORY AGENT; NORTRIPTYLINE; OPIATE; OXYCODONE; PARACETAMOL; TRAMADOL; UNINDEXED DRUG;

ALLODYNIA; ARTICLE; CANCER PAIN; COGNITIVE DEFECT; CONFUSION; CONSTIPATION; CONTROLLED RELEASE FORMULATION; DISEASE SEVERITY; DROWSINESS; DRUG DOSE TITRATION; DRUG HYPERSENSITIVITY; DRUG OVERDOSE; EUROPE; GASTROINTESTINAL DISEASE; HALLUCINATION; HUMAN; HYPERALGESIA; KIDNEY DISEASE; LIVER DYSFUNCTION; MEDICAL SOCIETY; MYOCLONUS EPILEPSY; NAUSEA AND VOMITING; NEUROPATHIC PAIN; NEUROSURGERY; PAIN ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; PRURITUS; QUALITY OF LIFE; RATING SCALE; SELF REPORT; TERMINAL CARE; URINE RETENTION; VISUAL ANALOG SCALE;

ANALGESICS; ANALGESICS, NON-NARCOTIC; ANALGESICS, OPIOID; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; EUROPE; GENERAL SURGERY; HUMANS; INCIDENCE; KETAMINE; NEOPLASMS; PAIN; RADIOTHERAPY; RISK ASSESSMENT;

EID: 77954316713     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq224     Document Type: Article

References (14)

1. Caraceni A, Cherny N, Fainsinger R et al. The Steering Committee of the EAPC Research Network. Pain measurement tools and methods in clinical research in palliative care: recommendations of an expert working group of the European Association of Palliative Care. J Pain Symptom Manage 2002; 23: 239-255.
2. Mercadante S, Radbruch L, Caraceni A . Episodic (breakthrough) pain. Consensus Conference of an expert working group of the European Association for Palliative Care. Cancer 2002; 94: 832-839.
3. Fallon M, Hanks G, Cherny N. Principles of control of cancer pain. BMJ 2006; 332: 1022-1024.
4. Cherny NI. How to deal with difficult pain problems. Ann Oncol 2005; 16 (Suppl 2): ii79-87.
5. Wool MS, Mor V. A multidimentional model for understanding cancer pain. Cancer Invest 2005; 23: 727-734.
6. Quigley C. The role of opioids in cancer pain. BMJ 2005; 331: 825-829.
7. Cherny NI. The pharmacologic management of cancer pain. Oncology 2004; 18: 1499-1515; discussion 1516, 1520-1524.
8. Luger NM, Mach DB, Sevcik MA, Mantyh PW. Bone cancer pain: from model to mechanism to therapy. J Pain Symptom Manage 2005; 29 (5 Suppl): S32-S46.
9. Cherny N, Ripamonti C, Pereira J et al. Strategies to manage the adverse effects of oral morphine. An evidence-based report. J Clin Oncol 2001; 19: 2542-2554.
10. Hanks GW, De Conno F, Ripamonti C . Morphine and alternative opioids in cancer pain: clinical recommendations. Expert Working group of the Research Network of the European Association for Palliative Care. Br J Cancer 2001; 84: 587-593.
11. Portenoy RK, Conn M. Cancer pain syndromes. In Bruera E, Portenoy RK (eds): Cancer pain: Assessment and Management. Cambridge: Cambridge University Press 2003; 89-110.
12. Mercadante S, Ferrera P, Villari P. Is there a ceiling effect of transdermal buprenorphine? Preliminary data in cancer patients. Support Care Cancer 2007; 15: 441-444.
13. Angst MS, Clark JD. Opioid-induced hyperalgesia: a qualitative systematic review. Anesthesiology 2006; 104: 570-587.
14. Cherny NI. Sedation for the care of patients with advanced cancer. Nat Clin Pract Oncol 2006; 3: 492-500.